Enliven Other Stockholder Equity vs Total Liab Analysis
| ELVN Stock | 25.41 0.02 0.08% |
Enliven Therapeutics financial indicator trend analysis is much more than just examining Enliven Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Enliven Therapeutics is a good investment. Please check the relationship between Enliven Therapeutics Other Stockholder Equity and its Total Liab accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.
Other Stockholder Equity vs Total Liab
Other Stockholder Equity vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Enliven Therapeutics Other Stockholder Equity account and Total Liab. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Enliven Therapeutics' Other Stockholder Equity and Total Liab is -0.07. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Total Liab in the same time period over historical financial statements of Enliven Therapeutics, assuming nothing else is changed. The correlation between historical values of Enliven Therapeutics' Other Stockholder Equity and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Enliven Therapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Other Stockholder Equity i.e., Enliven Therapeutics' Other Stockholder Equity and Total Liab go up and down completely randomly.
Correlation Coefficient | -0.07 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Other Stockholder Equity
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from Enliven Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Enliven Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.At this time, Enliven Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 22nd of November 2024, Enterprise Value is likely to grow to about 411.8 M, while Issuance Of Capital Stock is likely to drop about 505.3 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 22K | 1.1M | 12.0M | 12.6M | Cost Of Revenue | 99K | 622K | 297K | 252.6K |
Enliven Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Enliven Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Enliven Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 33.3M | 131.0M | 113.3M | 83.3M | 271.9M | 285.5M | |
| Other Current Liab | 2.5M | 565K | 3.1M | 6.0M | 25.0M | 26.3M | |
| Total Current Liabilities | 4.2M | 1.5M | 5.8M | 9.7M | 25.9M | 27.2M | |
| Total Stockholder Equity | (48.8M) | (20.3M) | (42.9M) | (76.8M) | 245.9M | 258.2M | |
| Net Debt | (4.9M) | (130.3M) | (109.9M) | (75.2M) | (99.8M) | (94.8M) | |
| Retained Earnings | (54.8M) | (20.5M) | (45.2M) | (82.9M) | (154.4M) | (146.7M) | |
| Accounts Payable | 1.7M | 808K | 2.5M | 3.4M | 532K | 505.4K | |
| Cash | 4.9M | 130.4M | 110.0M | 75.5M | 100.1M | 68.8M | |
| Cash And Short Term Investments | 28.9M | 130.4M | 110.0M | 75.5M | 253.1M | 265.8M | |
| Liabilities And Stockholders Equity | 33.3M | 131.0M | 113.3M | 83.3M | 271.9M | 285.5M | |
| Non Current Liabilities Total | 184.0K | 149.8M | 150.5M | 150.4M | 67K | 63.7K | |
| Other Current Assets | 1.7M | 222K | 646K | 2.2M | 13.0M | 13.7M | |
| Other Stockholder Equity | 5.9M | 157K | 2.3M | 6.2M | 400.2M | 420.2M | |
| Total Liab | 4.4M | 151.3M | 156.2M | 160.1M | 26.0M | 24.7M | |
| Total Current Assets | 30.6M | 130.6M | 110.7M | 77.8M | 266.2M | 279.5M |
Pair Trading with Enliven Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enliven Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enliven Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Enliven Stock
| 0.85 | VCNX | Vaccinex | PairCorr |
| 0.75 | GMAB | Genmab AS | PairCorr |
| 0.67 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.63 | LEGN | Legend Biotech Corp | PairCorr |
| 0.6 | FBRX | Forte Biosciences Trending | PairCorr |
The ability to find closely correlated positions to Enliven Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enliven Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enliven Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enliven Therapeutics to buy it.
The correlation of Enliven Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enliven Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enliven Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enliven Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.89) | Return On Assets (0.21) | Return On Equity (0.31) |
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.